Skip to content

Home / News

News

Stay at the forefront of drug delivery innovation in the contract development and manufacturing organization (CDMO) space. Explore our latest news and announcements, where the demands of today meet the possibilities of tomorrow.

Company announcement

Kindeva joins forces with Rocket Science Health to pioneer new Intranasal Delivery Platform

18 JUNE 2025: Kindeva, a global CDMO and drug delivery expert, and Rocket Science Health (RSH), a Canadian technology healthcare company, have joined forces to find partners to develop a new intranasal delivery platform. RSH’s cutting-edge technology, combined with Kindeva’s CDMO capabilities, will supercharge the product journey as RSH prepares for commercial readiness.  The non-exclusive […]
Read more

News filter

Kindeva Drug Delivery expands Loughborough, UK, facilities at Charnwood campus to support growth of green propellant commercialization

LOUGHBOROUGH, UK, WOODBURY, Minn., and ST. LOUIS, Mo.; June 4, 2024 (Business Wire) – Leading global drug-device combination product CDMO Kindeva Drug Delivery (Kindeva) today announced the expansion of their Loughborough, U.K., facilities at the Charnwood Campus Science Innovation and Technology Park. This strategic move by Kindeva supports the growth of green propellant commercialization and […]

Read more

Kindeva Global Health Security donates ATNAA to Ukraine through the European Commission’s rescEU and Governmental Strategic Reserves Agency (RARS)

WOODBURY, Minn. and ST. LOUIS, Mo.; May 29, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection […]

Read more

John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, named winner of RDD Conference’s Charles G. Thiel Award

Award for Outstanding Research and Discovery in Respiratory Drug Delivery WOODBURY, Minn. and ST. LOUIS, Mo.; May 8, 2024 (Business Wire) – At the recent Respiratory Drug Delivery (RDD) Conference, John Patton, Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (KDD), a global leader in drug-device […]

Read more

Kindeva Drug Delivery invests in second manufacturing line for greener inhalers at UK manufacturing site

WOODBURY, Minn. and ST. LOUIS, Mo.; May 6, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility. This new line will […]

Read more

Kindeva Drug Delivery and Syntegon install first Versynta microBatch in North America

Waiblingen, Germany/Minneapolis, USA, April 9, 2024. Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends. Kindeva is […]

Read more

Kindeva Drug Delivery welcomes Jennifer Riter, new Vice President of Analytical Services

WOODBURY, Minn. and ST. LOUIS, Mo.; March 18, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit. Riter comes to Kindeva from West Pharmaceutical where she spent the past […]

Read more

Kindeva Drug Delivery launches new Analytical Services Global Business Unit

WOODBURY, Minn. and ST. LOUIS, Mo.; Jan. 31, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector. For more than half […]

Read more

Kindeva Drug Delivery acquires Summit Biosciences, a specialized Nasal Drug Development and Manufacturing organization

WOODBURY, Minn., ST. LOUIS, Mo., LEXINGTON, Ky.; Jan. 18, 2024 (Business Wire) Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track […]

Read more

Nutriband signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse deterrent fentanyl patch

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) […]

Read more

Let’s transform tomorrow together

Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.